EAM
ACRV icon

Exome Asset Management’s Acrivon Therapeutics ACRV Stock Holding History

Exome Asset Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-116,757
Closed -$817K – 60
2024
Q3 		$817K Buy
+116,757
New +$920K 0.55% 50

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exome Asset Management's ACRV Position: Q4 2024 in Review

Exome Asset Management sold out of Acrivon Therapeutics (ACRV) in Q4 2024, closing a stake of 116,757 shares — an estimated $817K sold.

Exome Asset Management first reported a position in ACRV in Q3 2024 and held it in 1 quarter. The position peaked at $817K in Q3 2024. 63 funds tracked by Wall St. Rank hold ACRV as of Q4 2024.

  • Exome Asset Management reported no remaining Acrivon Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Exome Asset Management sold 116,757 Acrivon Therapeutics shares in Q4 2024, an estimated $817K.
  • Exome Asset Management first reported a position in Acrivon Therapeutics in Q3 2024 and held it in 1 quarter.
  • Exome Asset Management's Acrivon Therapeutics position peaked at $817K in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2024.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.